05/2026 – AstronDX and ADT Molecular are pleased to announce the award of two public health laboratory tenders in Malaysia for the supply of AstronDX proprietary LyteStar™ MDx kits.
The awards include the LyteStar™ TB/NTM PCR Kit 3.1 and the LyteStar™ COVID/Flu/RSV Differentiation RT-PCR Kit 1.0, supporting ongoing infectious disease screening, surveillance, and public health monitoring activities.
Notably, the LyteStar™ TB/NTM PCR Kit 3.1 has secured a repeat award, reflecting continued confidence in the performance, reliability, and clinical value of the assay for the detection and differentiation of Mycobacterium tuberculosis complex and non-tuberculous mycobacteria.
The latest awards further strengthen the growing adoption of the LyteStar™ product portfolio by public health laboratories and underscore AstronDX’s commitment to delivering high-quality molecular diagnostics tailored to the needs of healthcare providers and public health authorities across the region.
As emerging and infectious diseases continue to pose significant public health challenges, AstronDX remains dedicated to advancing accessible, accurate, and dependable diagnostic solutions that support disease surveillance, outbreak preparedness, and improved patient outcomes.
